Equities research analysts at Royal Bank Of Canada initiated coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report issued on Thursday, The Fly reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on GILD. ValuEngine downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a research note on Wednesday, June 21st. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, Leerink Swann reiterated a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. Eleven research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $83.06.

Gilead Sciences (NASDAQ GILD) traded down 1.679% on Thursday, reaching $82.275. The company’s stock had a trading volume of 8,693,280 shares. The company has a market capitalization of $107.45 billion, a price-to-earnings ratio of 8.936 and a beta of 1.19. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The firm’s 50 day moving average price is $76.43 and its 200-day moving average price is $69.93.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the previous year, the business earned $3.08 EPS. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. Equities analysts forecast that Gilead Sciences will post $8.75 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/14/royal-bank-of-canada-begins-coverage-on-gilead-sciences-inc-gild.html.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. Insiders sold 466,819 shares of company stock valued at $36,740,240 over the last 90 days. Company insiders own 1.30% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. grew its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 267 shares in the last quarter. Penserra Capital Management LLC grew its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares in the last quarter. Webster Bank N. A. grew its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences in the second quarter valued at approximately $147,000. Institutional investors and hedge funds own 74.05% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

The Fly

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.